Ormond Beach Clinical Research

Ormond Beach, Florida 32174-8196

4 studies enrolling now · 13 studies all time

What they study most

COVID-19, Cardiovascular Disease, Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease, Cytomegalovirus Infection, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Heart Failure, Heart Failure With Mildly Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Hypertension, Obesity

Studies at this site

• EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease — Recruiting now
• OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity — Recruiting now
• A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — Running, not enrolling
• A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — Running, not enrolling
• A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age — Stopped early
• Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection — Completed
• A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications. — Completed
• PBI-0451 (Pomotrelvir) Phase 2 Study in Nonhospitalized Symptomatic Adults With COVID-19 — Stopped early
• Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee — Completed
• Gan & Lee Evaluation of New Biosimilar for Type 1 Lispro — Withdrawn before enrolling